• 1
    Chien CT, Lee PH, Chen CF, Ma MC, Lai MK, Hsu SM. De novo demonstration and co-localization of free-radical production and apoptosis formation in rat kidney subjected to ischemia/reperfusion. J Am Soc Nephrol 2001; 12: 973982.
  • 2
    Chatterjee PK, Patel NSA, Kvale EO et al. Inhibition of inducible nitric oxide synthase reduces renal ischemia/reperfusion injury. Kidney Int 2002; 61: 862871.
  • 3
    Paller MS, Hoidal JR, Ferris TF. Oxygen free radicals in ischemic acute renal failure in the rat. J Clin Invest 1984; 74: 11561164.
  • 4
    De Vries B, Walter SJ, Peutz-Kootstra CJ, Wolfs TG, Van Heurn LW, Buurman WA. The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury. Am J Pathol 2004; 165: 16771688.
  • 5
    Fiane AE, Videm V, Lingaas PS et al. Mechanism of complement activation and its role in the inflammatory response after thoracoabdominal aortic aneurysm repair. Circulation 2003; 108: 849856.
  • 6
    Kaminski KA, Bonda TA, Korecki J, Musial WJ. Oxidative stress and neutrophil activation—the two keystones of ischemia/reperfusion injury. Int J Cardiol 2002; 86: 4159.
  • 7
    Xu Y, Huo Y, Toufektsian MC et al. Activated platelets contribute importantly to myocardial reperfusion injury. Am J Physiol 2006; 290: H692H699.
  • 8
    Kalweit G, Bach J, Huwer H, Winning J, Hellstern P. The impact of cardiac ischemia and reperfusion on markers of activated haemostasis and fibrinolysis during cardiopulmonary bypass: Comparison of plasma levels in arterial and coronary venous blood. Thromb Res 2005; 116: 3339.
  • 9
    Di Giorno C, Pinheiro HS, Heinke T et al. Beneficial effect of N-acetyl-cysteine on renal injury triggered by ischemia and reperfusion. Transplant Proc 2006; 38: 27742776.
  • 10
    Shuaib A, Lees KR, Lyden P et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007; 357: 562571.
  • 11
    Burns KE, Chu MW, Novick RJ et al. Perioperative N-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing cabg surgery: A randomized controlled trial. JAMA 2005; 294: 342350.
  • 12
    Takada M, Nadeau KC, Shaw GD, Marquette KA, Tilney NL. The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand. J Clin Invest 1997; 99: 26822690.
  • 13
    Singbartl K, Green SA, Ley K. Blocking P-selectin protects from ischemia/reperfusion-induced acute renal failure. FASEB J 2000; 14: 4854.
  • 14
    Dragun D, Lukitsch I, Tullius SG et al. Inhibition of intercellular adhesion molecule-1 with antisense deoxynucleotides prolongs renal isograft survival in the rat. Kidney Int 1998; 54: 21132122.
  • 15
    Dragun D, Tullius SG, Park JK et al. ICAM-1 antisense oligodesoxynucleotides prevent reperfusion injury and enhance immediate graft function in renal transplantation. Kidney Int 1998; 54: 590602.
  • 16
    Salmela K, Wramner L, Ekberg H et al. A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: A report of the European Anti-ICAM-1 Renal Transplant Study Group. Transplantation 1999; 67: 729736.
  • 17
    Fitch JC, Rollins S, Matis L et al. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 1999; 100: 24992506.
  • 18
    Shernan SK, Fitch JC, Nussmeier NA et al. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg 2004; 77: 942949.
  • 19
    Weisman HF, Bartow T, Leppo MK et al. Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990; 249: 146151.
  • 20
    Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. 3rd Ed. Oxford : Oxford University Press, 2004.
  • 21
    El Hamamsy I, Stevens LM, Carrier M et al. Effect of intravenous N-acetylcysteine on outcomes after coronary artery bypass surgery: A randomized, double-blind, placebo-controlled clinical trial. J Thorac Cardiovasc Surg 2007; 133: 712.
  • 22
    Tsikas D, Schwedhelm E, Suchy MT et al. Divergence in urinary 8-iso-PGF(2alpha) (iPF(2alpha)-III, 15-F(2t)-IsoP) levels from gas chromatography-tandem mass spectrometry quantification after thin-layer chromatography and immunoaffinity column chromatography reveals heterogeneity of 8-iso-PGF(2alpha). Possible methodological, mechanistic and clinical implications. J Chromatogr B 2003; 794: 237255.
  • 23
    Tsikas D. Simultaneous derivatization and quantification of the nitric oxide metabolites nitrite and nitrate in biological fluids by gas chromatography/mass spectrometry. Anal Chem 2000; 72: 40644072.
  • 24
    Londero D, Lo GP. Automated high-performance liquid chromatographic separation with spectrofluorometric detection of a malondialdehyde-thiobarbituric acid adduct in plasma. J Chromatogr A 1996; 729: 207210.
  • 25
    Mollnes TE, Lea T, Froland SS, Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 1985;22: 197202.
  • 26
    Van Berkel PH, Van Veen HA, Geerts ME, De Boer HA, Nuijens JH. Heterogeneity in utilization of N-glycosylation sites Asn624 and Asn138 in human lactoferrin: A study with glycosylation-site mutants. Biochem J 1996; 319: 117122.
  • 27
    Ingerslev J. A sensitive ELISA for von Willebrand factor (vWf:Ag). Scand J Clin Lab Invest 1987;47: 143149.
  • 28
    Lindeman JH, Abdul-Hussien H, Schaapherder AF et al. Enhanced expression and activation of pro-inflammatory transcription factors distinguish aneurysmal from atherosclerotic aorta: IL-6- and IL-8-dominated inflammatory responses prevail in the human aneurysm. Clin Sci 2008; 114: 687697.
  • 29
    Kleemann R, Verschuren L, De Rooij BJ et al. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 2004; 103: 41884194.
  • 30
    Land W, Zweler JL. Prevention of reperfusion-induced, free radical-mediated acute endothelial injury by superoxide dismutase as an effective tool to delay/prevent chronic renal allograft failure: A review. Transplant Proc 1997; 29: 25672568.
  • 31
    Pratico D, Lawson JA, FitzGerald GA. Cyclooxygenase-dependent formation of the isoprostane, 8-epi prostaglandin F2 alpha. J Biol Chem 1995; 270: 98009808.
  • 32
    Klein T, Neuhaus K, Reutter F, Nusing RM. Generation of 8-epi-prostaglandin F(2alpha) in isolated rat kidney glomeruli by a radical-independent mechanism. Br J Pharmacol 2001; 133: 643650.
  • 33
    Favreau F, Petit-Paris I, Hauet T et al. Cyclooxygenase 1-dependent production of F2-isoprostane and changes in redox status during warm renal ischemia-reperfusion. Free Radic Biol Med 2004; 36: 10341042.
  • 34
    Tomida T, Numaguchi Y, Nishimoto Y et al. Inhibition of COX-2 prevents hypertension and proteinuria associated with a decrease of 8-iso-PGF2alpha formation in L-NAME-treated rats. J Hypertens 2003; 21: 601609.
  • 35
    Dumanian GA, Heil BV, Khouri RK et al. Tissue factor and its inhibition at the human microvascular anastomosis. J Surg Res 1996; 60: 263269.
  • 36
    Brodsky SV, Yamamoto T, Tada T et al. Endothelial dysfunction in ischemic acute renal failure: Rescue by transplanted endothelial cells. Am J Physiol 2002; 282: F1140F1149.
  • 37
    De Vries B, Matthijsen RA, Wolfs TG, Van Bijnen AA, Heeringa P, Buurman WA. Inhibition of complement factor C5 protects against renal ischemia-reperfusion injury: Inhibition of late apoptosis and inflammation. Transplantation 2003; 75: 375382.
  • 38
    Norwood MG, Bown MJ, Sutton AJ, Nicholson ML, Sayers RD. Interleukin 6 production during abdominal aortic aneurysm repair arises from the gastrointestinal tract and not the legs. Br J Surg 2004; 91: 11531156.
  • 39
    Ghosh J, Khwaja N, Howarth V et al. Colonic epithelial apoptosis during conventional and endoluminal aortic surgery. Br J Surg 2005;92: 443448.
  • 40
    Guidi L, Tricerri A, Costanzo M et al. Interleukin-6 release in the hepatic blood outflow during normothermic liver ischaemia in humans. Dig Liver Dis 2003; 35: 409415.
  • 41
    Wan S, DeSmet JM, Barvais L, Goldstein M, Vincent JL, LeClerc JL. Myocardium is a major source of proinflammatory cytokines in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1996; 112: 806811.
  • 42
    Neumann FJ, Ott I, Gawaz M et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995;92: 748755.
  • 43
    Rowlands TE, Homer-Vanniasinkam S. Pro- and anti-inflammatory cytokine release in open versus endovascular repair of abdominal aortic aneurysm. Br J Surg 2001;88: 13351340.
  • 44
    Fukatsu A, Matsuo S, Yuzawa Y, Miyai H, Futenma A, Kato K. Expression of interleukin 6 and major histocompatibility complex molecules in tubular epithelial cells of diseased human kidneys. Lab Invest 1993; 69: 5867.
  • 45
    Kawai M, Naruse K, Komatsu S et al. Mechanical stress-dependent secretion of interleukin 6 by endothelial cells after portal vein embolization: Clinical and experimental studies. J Hepatol 2002; 37: 240246.
  • 46
    De Kruif MD, Lemaire LC, Giebelen IA et al. Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia. J Immunol 2007; 178: 18451851.
  • 47
    Scheller J, Rose-John S. Interleukin-6 and its receptor: From bench to bedside. Med Microbiol Immunol (Berl) 2006; 195: 173183.
  • 48
    Camargo CA, Jr., Madden JF, Gao W, Selvan RS, Clavien PA. Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology 1997; 26: 15131520.
  • 49
    Tiberio L, Tiberio GA, Bardella L et al. Mechanisms of interleukin-6 protection against ischemia-reperfusion injury in rat liver. Cytokine 2006; 34: 131142.
  • 50
    Matsumoto T, O’Malley K, Efron PA et al. Interleukin-6 and STAT3 protect the liver from hepatic ischemia and reperfusion injury during ischemic preconditioning. Surgery 2006; 140: 793802.
  • 51
    Matsushita K, Iwanaga S, Oda T et al. Interleukin-6/soluble interleukin-6 receptor complex reduces infarct size via inhibiting myocardial apoptosis. Lab Invest 2005; 85: 12101223.
  • 52
    Nechemia-Arbely Y, Barkan D, Pizov G et al. IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol 2008; 19: 11061115.
  • 53
    Homsi E, Ribeiro-Alves MA, Lopes de Faria JB, Dias EP. Interleukin-6 stimulates tubular regeneration in rats with glycerol-induced acute renal failure. Nephron 2002; 92: 192199.
  • 54
    Patel NS, Chatterjee PK, Di Paola R et al. Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion. J Pharmacol Exp Ther 2005; 312: 11701178.
  • 55
    Kielar ML, John R, Bennett M et al. Maladaptive role of IL-6 in ischemic acute renal failure. J Am Soc Nephrol 2005; 16: 33153325.
  • 56
    Kelso A, Troutt AB, Maraskovsky E et al. Heterogeneity in lymphokine profiles of CD4+ and CD8+ T cells and clones activated in vivo and in vitro. Immunol Rev 1991; 123: 85114.
  • 57
    Mukaida N. Interleukin-8: An expanding universe beyond neutrophil chemotaxis and activation. Int J Hematol 2000; 72: 391398.
  • 58
    Cognasse F, Hamzeh-Cognasse H, Lafarge S et al. Human platelets can activate peripheral blood B cells and increase production of immunoglobulins. Exp Hematol 2007; 35: 13761387.